Replies to post #161572 on Cytodyn Inc (CYDY)

[misiu143]

3X ..I am not sure I agree with all about our studies ..

We know that the smaller the study the more difficult is to prove it ..and we did ..

Starting with CD10 , all BP will like to have our results in NEWS2 endpoints , and if they will have our results , they will have EUA given by FDA after phase 2 in this pandemic long time ago ..

It was tragic for ALL Americans that FDA didn’t do that with a drug from a small biotech CYDY.,

And CD12 , FDA made a joke of it , if they will approved a protocol for Leronlimab for the same adaptive design study as they did for Remdesivir and Lenzilumab , our management will know results during the study as they did , change primary endpoint to length of hospitalization and we be SS and no one will call our drug leronsaline .
And very important they will know that in the study drug patients were mostly over 65 and placebo under .,

But FDA didn’t do that to other companies .
They approved these studies for Remdesivir and Leronlimab .,

I have my opinion about effect of Remdesivir , after this study I also have about Lenzilumab .,
If one need to go to this manipulation it must be a reason .

All imo

[LifeLongLearner]

3X,

6 months ago I was with you on management m. However, the more we learn about the trials and the FDA, I don’t think it would matter who was running CYDY. There are clearly a lot of powerful players that don’t want to see Leronlimab approved for anything.

I’m actually coming over to the view that NP is exactly the leader we need right now. He is driven and doesn’t give up. Considering the strong head winds we are facing, his strengths are what we need (at least until we get to our first approval).

I think NP is bringing more to the party than you are willing to acknowledge.